Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 170

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype

Open access
McCullough, Marjorie L., Patel, Alpa V., Patel, Roshni, Rodriguez, Carmen, Feigelson, Heather Spencer, Bandera, Elisa V., Gansler, Ted, Thun, Michael J., Calle, Eugenia E.·2008·Cancer Epidemiology, Biomarkers & Prevention

Abstract

Epidemiologic studies unequivocally show that greater body mass increases the risk of endometrial cancer, but whether risk varies by use of postmenopausal hormone therapy (HT), location of fat deposition, or cancer subtype is still unclear. We examined these associations among 33,436 postmenopausal women in the Cancer Prevention Study II Nutrition Cohort, who completed questionnaires on diet, lifestyle, and medical history at baseline in 1992. A total of 318 cases were eligible through June 2003. Cox-proportional hazards analyses were used to estimate multivariate-adjusted rate ratios (RR). As expected, adult body mass index (BMI) was a strong predictor of risk [RR, 4.70; 95% confidence interval (CI), 3.12-7.07 for BMI 35+ versus 22.5-25.0, P trend < 0.0001]. Use of estrogen plus progestin postmenopausal HT modified the association. Among never-users, risk was significantly linear across the entire range of BMI examined (RR, 0.51; 95% CI, 0.29-0.92 for <22.5 versus 22.5-25.0; RR, 4.41; 95% CI, 2.70-7.20 for ≥35 versus 22.5-25.0, P trend < 0.0001), but among ever estrogen plus progestin users, the association was not significant (P trend = 1.0; P interaction < 0.0001). We observed no difference in risk according to tendency for central versus peripheral fat deposition. Greater BMI (≥30 versus <25.0) increased risk of both “type I” (classic estrogen pathway, RR, 4.22; 95% CI, 3.07-5.81) and “type II” (serous, clear cell, and all other high grade) cancers (RR, 2.87; 95% CI, 1.59-5.16). The increased risk of endometrial cancer across the range of BMI in women who never used postmenopausal HT stresses the need to prevent both overweight and obesity in women. (Cancer Epidemiol Biomarkers Prev 2008;17(1):73–9)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-07-2567

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 170

Metadata

Authors
McCullough, M. L., Patel, A. V., Patel, R., Rodriguez, C., Feigelson, H. S., Bandera, E. V., Gansler, T., Thun, M. J., & Calle, E. E.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2008-01-01
Volume
17
Issue
1
Pages
73-79
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W1967421306
Cited by
170
References
6
FWCI
4.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype. https://app.cochat.ai/papers/10.1158/1055-9965.epi-07-2567
The paper
McCullough, M. L., Patel, A. V., Patel, R., Rodriguez, C., Feigelson, H. S., Bandera, E. V., Gansler, T., Thun, M. J., & Calle, E. E. (2008). Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-07-2567

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.